title: Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy.
abstract: The aim of the present study was to examine the causes of death, the mortality attributable to liver failure, and the impact of hepatitis virus infections on the survival of a cohort of HIV-infected patients before and after the extensive use of highly active antiretroviral therapy (HAART). Liver disease associated with hepatitis C virus (HCV) seems to be accelerated in patients infected with the human immunodeficiency virus (HIV). On the other hand, the effect of HCV on HIV progression was controversial before the introduction of HAART. However, the last study to report changes in mortality due to liver failure was published in 1997, and the impact of HCV carriage on the survival of HIV-infected patients receiving HAART needs to be clarified. In this investigation, 492 patients who were prescribed antiretroviral drugs between April 1989 and September 2000 were included in the study cohort. The median duration of follow-up of the cohort was 1,392 days. HCV infection was present in 323 (68%). Mortality attributable to AIDS decreased from 4.5 to 1.8 per 100 persons per year. Mortality due to liver failure increased from 0.3 to 0.5 per 100 persons per year ( P<0.01). The survival of patients with and without HCV infection was similar ( P=0.8). Although liver failure is an increasing cause of death among HIV-infected patients receiving HAART, HCV infection has still no impact on the survival of HIV-infected patients.
authors.affiliation: Servicio de Medicina Interna, Hospital Universitario de Valme, Ctra Cádiz, s/n, 41014 Seville, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Macías
authors.forename: I
authors.initials: I
authors.lastname: Melguizo
authors.forename: F J
authors.initials: FJ
authors.lastname: Fernández-Rivera
authors.forename: A
authors.initials: A
authors.lastname: García-García
authors.forename: J A
authors.initials: JA
authors.lastname: Mira
authors.forename: A J
authors.initials: AJ
authors.lastname: Ramos
authors.forename: J M
authors.initials: JM
authors.lastname: Rivera
authors.forename: J A
authors.initials: JA
authors.lastname: Pineda
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D000328:Adult; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D016022:Case-Control Studies; D002423:Cause of Death; D016009:Chi-Square Distribution; D015331:Cohort Studies; D005260:Female; D006526:Hepatitis C / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality*; D006801:Humans; D017093:Liver Failure / Q000401:mortality* / Q000821:virology; D008297:Male; D015999:Multivariate Analysis; D011336:Probability; D012016:Reference Values; D018570:Risk Assessment; D013030:Spain / Q000453:epidemiology; D016019:Survival Analysis